Most-Read News of 2022

Article

This year's most-read news on MHE features "Paxlovid Rebound: Rare But Real," "John Fetterman’s Atrial Fibrillation and Stroke: ‘I Almost Died’," "Pandemic Mortality Rate Much Lower in Canada Than in the US. Why?," and more.

  1. Paxlovid Rebound: Rare But Real
    Mayo Clinic researchers reported in the journal Clinical Infectious Diseases that less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19.
    Read more
  2. Diabetes Medications Find New Life as Weight-Loss Drugs
    Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite. But their cost-effectiveness is in question, and many payers are saying no to coverage — for now.
    Read more
  3. John Fetterman’s Atrial Fibrillation and Stroke: ‘I Almost Died’
    Lack of an adherence may have been a factor. The Democratic Senate candidate stopped taking the medications he was prescribed after being diagnosed with atrial fibrillation in 2017.
    Read more
  4. Childhood Insomnia Symptoms Often Persist into Adulthood, Study Finds
    Children with poor sleep had a 2.6-fold higher risk of developing adult insomnia, according to longitudinal research conducted by Penn State researchers.
    Read more
  5. Pandemic Mortality Rate Much Lower in Canada Than in the US. Why?
    Some researchers have pointed to the benefits of a single-payer system such as the one in Canada. But the author of the PNAS commentary, David Fisman, say it may be trace back to the more communitarian outlook of Canadians.
    Read more

Recent Videos
Jill Zouzoulas, MD, FACR, an expert on biologic therapies
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Video 5 - "Obstacles in Adapting Diabetes Technology to Individual Needs" - 1 KOL is featured
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Related Content
© 2024 MJH Life Sciences

All rights reserved.